StockIQ.techAgilent Technologies, Inc. (A) Stock Analysis
Free AI-powered analysis and research for Agilent Technologies, Inc. stock
Sector: Healthcare
A snapshot
Data as of 4 Nov 2026 close. Updated daily.
Agilent Technologies, Inc. scores 77/100 on StockIQ's model, which reads as strongly positive signals overall. The price is above its 200-day average and at 94% of its 52-week range, up 22.3% over the past year. Latest reported figures show a profit margin of 19.5%, return on equity of 21.0% and revenue growth of +8.1%.
What is driving the score
- RSI Neutral: +5
- Strong Uptrend: +12
- MACD Bearish: -8
- High P/E (35.6): -10
- Good Profit Margin (19.5%): +5
- Strong Liquidity (2.05 Current Ratio): +8
- Excellent ROE (21.0%): +8
- High P/B (6.92): -5
- Strong Long-term Uptrend: +8
- Healthy Momentum (+22.3% over 1 year): +7
- Low Volume (0.3x): -3
Automated, general information only – not financial advice. Scores can be wrong. How the score works
Full A report
Agilent Technologies, Inc. (A) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.
Analyze A Now →📰 Latest Update
Microarray Analysis - Global Strategic Business Report 2026: Secure Share in a $5.1 Billion Market by 2032, Featuring Profiles of Key Players Agilent, Illumina, Roche and Thermo Fisher
Wed, November 4, 2026 at 4:31 PM UTC 2 min read
The global microarray analysis market, valued at US$3.3 billion in 2025, is projected to reach US$5.1 billion by 2032, growing at a CAGR of 6.3%. Key drivers include advancements in genomics research, personalized medicine demand, and increased use in molecular diagnostics. The report highlights significant growth opportunities in the consumables and software segments, with notable contributions from major players like Agilent, Illumina, Roche, and Thermo Fisher, as well as regional growth in markets such as China and the U.S.